Treatment News : Victrelis Ups Hep C Cure Rates in Those Coinfected With HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 22, 2013

Victrelis Ups Hep C Cure Rates in Those Coinfected With HIV

The protease inhibitor Victrelis (boceprevir), when added to a regimen of interferon and ribavirin, vastly improves cure rates of hepatitis C virus (HCV) and does not raise significant treatment risks among people coinfected with HIV, according to findings published in The Lancet and reported by the Skin & Allergy News Digital Network. The investigators conducted a double-blind, randomized, controlled Phase II trial of 99 coinfected adults who had untreated genotype 1 of hep C and an undetectable HIV viral load. The study was conducted at 30 sites throughout 2010.

The participants were randomized into two treatment groups at a ratio of one to two. All of them began with just pegylated interferon and ribavirin for four weeks. Then the smaller control group added a placebo, and the rest of the participants received Victrelis three times daily. The trial continued for 44 weeks.

Ninety-eight participants received at least one dose of treatment, including 64 in the group taking Victrelis and 34 in the control arm. Twenty-four weeks after completing treatment, 63 percent of those in the Victrelis arm achieved a sustained virologic response (SVR, considered a cure), compared with just 29 percent of the control group.

Adverse events were higher in the Victrelis group when compared with the control, including anemia (a respective 41 vs. 26 percent), fever (36 vs. 21 percent), diminished appetite (34 vs. 18 percent), a distortion in the sense of taste (28 vs. 15 percent), vomiting (28 vs. 15 percent) and neutropenia (19 vs. 6 percent), which is an abnormally low count of certain white blood cells key for fighting infections.

To read the Lancet abstract, click here.

To read the Skin & Allergy News story, click here.

Search: Victrelis, boceprevir, hepatitis C, HIV, coinfection, ribavirin, pegylated interferon, Skin & Allergy News Digital Network, cure, sustained virologic response, SVR.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    charliehunter
    San Francisco
    California


    Newhopenate
    New Hope
    Pennsylvania


    Deelight4u
    BROOKLYN
    New York


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.